246 related articles for article (PubMed ID: 17715126)
1. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
Garnier T; Mäntylä A; Järvinen T; Lawrence J; Brown M; Croft S
J Antimicrob Chemother; 2007 Oct; 60(4):802-10. PubMed ID: 17715126
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone.
Mäntylä A; Garnier T; Rautio J; Nevalainen T; Vepsälainen J; Koskinen A; Croft SL; Järvinen T
J Med Chem; 2004 Jan; 47(1):188-95. PubMed ID: 14695832
[TBL] [Abstract][Full Text] [Related]
3. Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis.
Garnier T; Mäntylä A; Järvinen T; Lawrence MJ; Brown MB; Croft SL
J Pharm Pharmacol; 2007 Jan; 59(1):41-9. PubMed ID: 17227619
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives.
Mäntylä A; Rautio J; Nevalainen T; Vepsälainen J; Juvonen R; Kendrick H; Garnier T; Croft SL; Järvinen T
Bioorg Med Chem; 2004 Jul; 12(13):3497-502. PubMed ID: 15186834
[TBL] [Abstract][Full Text] [Related]
6. In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis.
Garnier T; Brown MB; Lawrence MJ; Croft SL
J Pharm Pharmacol; 2006 Aug; 58(8):1043-54. PubMed ID: 16872550
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
[TBL] [Abstract][Full Text] [Related]
8. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
[TBL] [Abstract][Full Text] [Related]
10. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis.
Eissa MM; Amer EI; El Sawy SM
Exp Parasitol; 2011 Aug; 128(4):382-90. PubMed ID: 21620834
[TBL] [Abstract][Full Text] [Related]
11. Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis.
Thapa R; Mondal S; Riikonen J; Rantanen J; Näkki S; Nissinen T; Närvänen A; Lehto VP
PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009533. PubMed ID: 34185780
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo prophylactic and curative activity of the triterpene saponin PX-6518 against cutaneous Leishmania species.
Inocêncio da Luz RA; Vermeersch M; Deschacht M; Hendrickx S; Van Assche T; Cos P; Maes L
J Antimicrob Chemother; 2011 Feb; 66(2):350-3. PubMed ID: 21131319
[TBL] [Abstract][Full Text] [Related]
13. Activity of physalins purified from Physalis angulata in in vitro and in vivo models of cutaneous leishmaniasis.
Guimarães ET; Lima MS; Santos LA; Ribeiro IM; Tomassini TB; Ribeiro dos Santos R; dos Santos WL; Soares MB
J Antimicrob Chemother; 2009 Jul; 64(1):84-7. PubMed ID: 19454526
[TBL] [Abstract][Full Text] [Related]
14. Formulation and evaluation of oil-in-water emulsions of piperine in visceral leishmaniasis.
Veerareddy PR; Vobalaboina V; Nahid A
Pharmazie; 2004 Mar; 59(3):194-7. PubMed ID: 15074591
[TBL] [Abstract][Full Text] [Related]
15. Potential of doxorubicin as an antileishmanial agent.
Sett R; Basu N; Ghosh AK; Das PK
J Parasitol; 1992 Apr; 78(2):350-4. PubMed ID: 1556650
[TBL] [Abstract][Full Text] [Related]
16. Antileishmanial effect of cisplatin against murine visceral leishmaniasis.
Kaur S; Sachdeva H; Dhuria S; Sharma M; Kaur T
Parasitol Int; 2010 Mar; 59(1):62-9. PubMed ID: 19853668
[TBL] [Abstract][Full Text] [Related]
17. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.
Nakayama H; Loiseau PM; Bories C; Torres de Ortiz S; Schinini A; Serna E; Rojas de Arias A; Fakhfakh MA; Franck X; Figadère B; Hocquemiller R; Fournet A
Antimicrob Agents Chemother; 2005 Dec; 49(12):4950-6. PubMed ID: 16304157
[TBL] [Abstract][Full Text] [Related]
19. Antileishmanial effect of free and encapsulated sinefungin against Leishmania donovani infections in BALB/c mice.
Neal RA; Iwobi MV; Robert-Gero M
C R Acad Sci III; 1989; 308(18):485-8. PubMed ID: 2508995
[TBL] [Abstract][Full Text] [Related]
20. Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani.
Chen M; Christensen SB; Theander TG; Kharazmi A
Antimicrob Agents Chemother; 1994 Jun; 38(6):1339-44. PubMed ID: 8092835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
